Complementary NAD+ replacement strategies fail to functionally protect dystrophin-deficient muscle

Skeletal Muscle

Daniel C. Sévin¹  Johanna Vappiani¹  Eugene L. Stewart²  John C. Ulrich³  J. David Becherer³  Alan V. McDougal³  David W. Frederick³  Melisa Semenas³  H. Fritz Kramer³  Frank Preugschat³  Andrea Nuzzo⁴ 

[1] Cellzome, GlaxoSmithKline R&D, Heidelberg, Germany;Computational Sciences, Molecular Design, GlaxoSmithKline R&D, Collegeville, PA, USA;Muscle Metabolism Unit, GlaxoSmithKline R&D, Research Triangle Park, NC, Collegeville, PA, USA;Target Sciences, Computational Biology, GlaxoSmithKline R&D, Collegeville, PA, USA;

关键词: MDX;    NAD+;    CD38;    NR;    Eccentric;    Injury;    Metabolomics;    Therapeutics;   

DOI  :  10.1186/s13395-020-00249-y

来源: Springer

【 摘 要 】

BackgroundDuchenne muscular dystrophy (DMD) is a progressive muscle wasting disorder stemming from a loss of functional dystrophin. Current therapeutic options for DMD are limited, as small molecule modalities remain largely unable to decrease the incidence or mitigate the consequences of repetitive mechanical insults to the muscle during eccentric contractions (ECCs).MethodsUsing a metabolomics-based approach, we observed distinct and transient molecular phenotypes in muscles of dystrophin-deficient MDX mice subjected to ECCs. Among the most chronically depleted metabolites was nicotinamide adenine dinucleotide (NAD), an essential metabolic cofactor suggested to protect muscle from structural and metabolic degeneration over time. We tested whether the MDX muscle NAD pool can be expanded for therapeutic benefit using two complementary small molecule strategies: provision of a biosynthetic precursor, nicotinamide riboside, or specific inhibition of the NAD-degrading ADP-ribosyl cyclase, CD38.ResultsAdministering a novel, potent, and orally available CD38 antagonist to MDX mice successfully reverted a majority of the muscle metabolome toward the wildtype state, with a pronounced impact on intermediates of the pentose phosphate pathway, while supplementing nicotinamide riboside did not significantly affect the molecular phenotype of the muscle. However, neither strategy sustainably increased the bulk tissue NAD pool, lessened muscle damage markers, nor improved maximal hindlimb strength following repeated rounds of eccentric challenge and recovery.ConclusionsIn the absence of dystrophin, eccentric injury contributes to chronic intramuscular NAD depletion with broad pleiotropic effects on the molecular phenotype of the tissue. These molecular consequences can be more effectively overcome by inhibiting the enzymatic activity of CD38 than by supplementing nicotinamide riboside. However, we found no evidence that either small molecule strategy is sufficient to restore muscle contractile function or confer protection from eccentric injury, undermining the modulation of NAD metabolism as a therapeutic approach for DMD.

【 授权许可】

CC BY